Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases

References

• . Buckley RH, ed. Diagnostic and Clinical Care Guidelines for Primary Immunodeficiency Diseases, Second Edition. Towson, MD: Immune Deficiency Foundation; 2009
   Google Scholar
• . Eades-Perner AM, Gathmann B, Knerr V, ; ESID Registry Working Party. The European internet-based patient and research database for primary immunodeficiencies: Results 2004–06. Clin Exp Immunol. 2007; 147(2):306–312
   PubMed Web of Science ®Google Scholar
• . Bjorkander J, Chapel H, Spickett G. Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous immunoglobulin in the prevention of infections in patients with primary antibody deficiency syndromes. Mol Immunol. 1998; 35:11–12
   Web of Science ®Google Scholar
• . Cunningham-Rundles C, Siegal FP, Smithwick EM, . efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984; 101(4):435–439
   PubMed Web of Science ®Google Scholar
• . Lederman HM, Roifman CM, Lavi S, Gelfand E W. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med. 1986; 81(3):443–446
   PubMed Web of Science ®Google Scholar
• . Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991; 338(8760):162–166
   PubMed Web of Science ®Google Scholar
• . Gardulf A, Andersen V, Bjorkander J, . Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet. 1995; 345(8946):365–369
   PubMed Web of Science ®Google Scholar
• . Gardulf A, Nicolay U, Math D, . Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004; 114(4):936–942
   PubMed Web of Science ®Google Scholar
• . Nicolay U, Kiessling P, Berger M, . Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006; 26(1):65–72
   PubMed Web of Science ®Google Scholar
• . Berger M, Murphy E, Riley P, Bergman GE; VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010; 103(9):856–863
   PubMed Web of Science ®Google Scholar
• . Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH; Vivaglobin Study Group. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010; 15(6):238–245
   PubMed Web of Science ®Google Scholar
• . Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008; 28(4):779–802, vii
   PubMed Web of Science ®Google Scholar
• . Simoens S. Pharmacoeconomics of immunoglobulins in primary immunodeficiency. Expert Rev Pharmacoecon Outcomes Res. 2009; 9(4):375–386
   PubMedGoogle Scholar
• . Immune Deficiency Foundation. Primary Immunodeficiency Diseases in America: The Third National Survey of Patients. http://primaryimmune.org/idf-survey-research-center/idf-surveys/patient-surveys. Published May 1, 2009. Accessed July 22, 2011
   Google Scholar
• . Draft Guidance. E7 Studies in Support of Special Populations: Geriatrics. Questions & Answers. 2009. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org. Accessed August 15, 2011
   Google Scholar
• . Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011; 139(2):133–141
   PubMed Web of Science ®Google Scholar
• . Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: Reasons and regimens. Allergy Asthma Clin Immunol. 2005; 1(3):120–130
   PubMedGoogle Scholar
• . Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006; 26(3): 265–273
   PubMed Web of Science ®Google Scholar
• . Desai SH, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009; 124(4):854–856
   PubMed Web of Science ®Google Scholar
• . Hagan JB, Fasano MB, Spector S, . efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010; 30(5):734–745
   PubMed Web of Science ®Google Scholar
• . Thepot S, Malphettes M, Gardeur A, . Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: Decreasing dosage does not alter serum IgG levels. J Clin Immunol. 2010; 30(4):602–606
   PubMed Web of Science ®Google Scholar
• . Food and Drug Administration. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm072130.htm. Accessed May 3, 2011
   Google Scholar
• . Wasserman RL, Irani AM, Tracy J, . Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010; 161(3):518–526
   PubMed Web of Science ®Google Scholar
• . Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010; 125(6):1354–1360 e1354
   PubMed Web of Science ®Google Scholar
• . Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006; 26(4):400–405
   PubMed Web of Science ®Google Scholar